Bristol-myers Squibb Compnay

John L Gilmore

Alaric J Dyckman

James Edward Sheppeck

T G Murali Dhar

Hai-Yun Xiao

Michael G Yang

Zili Xiao

Trevor C Sherwood

Brian K Whiteley

Dharmpal S Dodd

David Marcoux

David S Weinstein

Sreekantha Ratna Kumar

Christopher P Mussari

Laxman Pasunoori

Subramanya Hegde

Bingwei Vera Yang

Srinivasan Kunchithapatham Duraisamy

Rushith Kumar Anumula

Pitani Veera Venkata Srinivas

Shoshana L Posy

Tasir Shamsul Haque

Jingwu Duan

Soong-Hoon Kim

Wayne D Vaccaro

Bin Jiang

Lidia M Doweyko

John E Macor

William John Pitts

Chunjian Liu

Steven H Spergel

Louis John Lombardo

Ramesh Kumar Sistla

Xiao-Tao Chen

Jianmin Wang

Qingjie Liu

David R Tortolani

Arthur M P Doweyko

Ryan M Moslin

Michael E Mertzman

Yanlei Zhang

Anupama Kandhi Ramachandra Reddy

Ling Li

Tg Murali Dhar

Xiaohua He

Arthur M Doweyko

Bryan W King

Chunjian C Liu

TG Murali Dhar

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of IL-12, IL-23 and/or IFN-alpha

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CRor N; and G, A, R; and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole and indazole compounds

Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G, G, L, R, R, R, R, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole dimer compounds

Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R, R, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole compounds useful as TLR inhibitors

4-azaindole compounds

Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R, R, R, R, R, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Substituted indole compounds

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein Ris &#x2014;OH or &#x2014;OP(O)(OH), and X, X, X, R, R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Substituted bicyclic compounds

Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R, R, R, R, and Rare as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN&#x3b1;, by acting on Tyk-2 to cause signal transduction inhibition. 

Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFN&#x3b1; responses

Disclosed are compounds of Formula (I) or a salt thereof, wherein: Y is Formula (II), or Formula (III); R, R, R, R, R, R, R, R, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases. 

Substituted indole compounds useful as inhibitors of TLR7/8/9

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: X is &#x2014;CH&#x2014; or &#x2014;C(O)&#x2014;; Ris &#x2014;OH or &#x2014;OP(O)(OH); L is a bond, &#x2014;CH&#x2014;, or &#x2014;C(O)&#x2014;; Ris n-Calkyl; each Ris independently selected from Cl and &#x2014;CH; and n is zero, 1, or 2; provided that if X is &#x2014;CH&#x2014;, then L is &#x2014;CH&#x2014; or &#x2014;C(O)&#x2014;. Also disclosed are methods of using such compounds as selective agonists for G protein coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 

Alkylphenyl compounds

4-Azaindole compounds

Growing community of inventors

Yardley, PA, United States of America

John L Gilmore